NABGEN, INC.
Novel strategy to block AAV neutralizing antibody activity
Novel strategy to block AAV neutralizing antibody activity is a funding opportunity from NABGEN, INC., up to 993865, closing August 31, 2028.
Aug 31, 2028
(762d left)Overview
Adeno-associated virus (AAV) vectors have been successfully applied in clinical trials in patients with different genetic disorders. However, the high prevalence of neutralizing antibodies (Nabs) is one of major concerns to limit the broad AAV application in clinics. In humans, approximately 50% of the population has…